Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study

Jian Li, Lin Shen, Yongjian Zhou et al.|Clinical Cancer Research|2022

Cited by 15